8.9996

1.01% 0.0996

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $8.9996, with a volume of 2.14M. It is up +1.01% in the last 24 hours and down -24.45% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Previous Close:

$8.90

Open:

$8.9

24h Volume:

2.14M

Relative Volume:

1.99

Market Cap:

$983.11M

Revenue:

Net Income/Loss:

$-227.05M

P/E Ratio:

-4.0907

EPS:

-2.2

Net Cash Flow:

$-177.93M

1W Performance:

-13.56%

1M Performance:

-24.45%

6M Performance:

+20.83%

1Y Performance:

+12.66%

1-Day Range:

$8.56

$9.075

1-Week Range:

$8.56

$11.16

52-Week Range:

$3.67

$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

164

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT	9.00	983.11M	0	-227.05M	-177.93M	-2.20
VRTX	467.79	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	761.02	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.78	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.27	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.65	24.08B	3.30B	-501.07M	1.03B	11.54

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

05:53 AM

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World

05:53 AM

02:36 AM

COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Nov 14, 2024

Nov 13, 2024

Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat

Nov 13, 2024

Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat

Nov 13, 2024

Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks

Nov 13, 2024

Nov 12, 2024

Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com

Nov 12, 2024